ALK-Abello A/S
CSE:ALK B

Watchlist Manager
ALK-Abello A/S Logo
ALK-Abello A/S
CSE:ALK B
Watchlist
Price: 171 DKK 0.71% Market Closed
Market Cap: 34.6B DKK
Have any thoughts about
ALK-Abello A/S?
Write Note

Relative Value

The Relative Value of one ALK B stock under the Base Case scenario is 222.5 DKK. Compared to the current market price of 171 DKK, ALK-Abello A/S is Undervalued by 23%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ALK B Relative Value
Base Case
222.5 DKK
Undervaluation 23%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
36
vs Industry
23
Median 3Y
6
Median 5Y
6.1
Industry
2.4
Forward
5.9
vs History
66
vs Industry
11
Median 3Y
51.2
Median 5Y
57.1
Industry
20.9
Forward
33.5
vs History
76
vs Industry
16
Median 3Y
41.3
Median 5Y
46.5
Industry
15.9
vs History
23
vs Industry
3
Median 3Y
81.8
Median 5Y
72.4
Industry
23.7
vs History
42
vs Industry
12
Median 3Y
6.3
Median 5Y
6.6
Industry
2
vs History
36
vs Industry
22
Median 3Y
6
Median 5Y
6.2
Industry
2.6
Forward
5.9
vs History
39
vs Industry
24
Median 3Y
9.5
Median 5Y
9.9
Industry
5
vs History
57
vs Industry
16
Median 3Y
28.2
Median 5Y
29.4
Industry
12.4
Forward
19.4
vs History
63
vs Industry
16
Median 3Y
37.6
Median 5Y
40.4
Industry
15.9
Forward
23.6
vs History
76
vs Industry
17
Median 3Y
42.3
Median 5Y
47
Industry
14.2
vs History
vs Industry
6
Median 3Y
84.9
Median 5Y
113.7
Industry
17.6
vs History
39
vs Industry
18
Median 3Y
4.5
Median 5Y
4.7
Industry
1.8

Multiples Across Competitors

ALK B Competitors Multiples
ALK-Abello A/S Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
DK
ALK-Abello A/S
CSE:ALK B
37.9B DKK 6.8 46.5 27.7 34.6
US
Eli Lilly and Co
NYSE:LLY
715.6B USD 14.6 64.4 34.7 37.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
366.8B USD 4.1 16.8 12.3 16.1
DK
Novo Nordisk A/S
CSE:NOVO B
1.9T DKK 6.7 19.3 12.7 14.5
CH
Roche Holding AG
SIX:ROG
206.8B CHF 3.4 25 9.4 11
CH
Novartis AG
SIX:NOVN
179.4B CHF 4 16.7 9.9 13.2
UK
AstraZeneca PLC
LSE:AZN
160.8B GBP 3.9 27.6 130.6 196.9
US
Merck & Co Inc
NYSE:MRK
194.3B USD 3 11.1 8.3 10.1
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
130.8B USD 2.1 16.6 7.2 10.1
P/E Multiple
Earnings Growth PEG
DK
ALK-Abello A/S
CSE:ALK B
Average P/E: 27.1
46.5
23%
2
US
Eli Lilly and Co
NYSE:LLY
64.4
50%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
16.8
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19.3
18%
1.1
CH
Roche Holding AG
SIX:ROG
25
32%
0.8
CH
Novartis AG
SIX:NOVN
16.7
17%
1
UK
AstraZeneca PLC
LSE:AZN
27.6
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.1
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
16.6
30%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DK
ALK-Abello A/S
CSE:ALK B
Average EV/EBITDA: 396.4
27.7
22%
1.3
US
Eli Lilly and Co
NYSE:LLY
34.7
31%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.3
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
12.7
14%
0.9
CH
Roche Holding AG
SIX:ROG
9.4
6%
1.6
CH
Novartis AG
SIX:NOVN
9.9
5%
2
UK
AstraZeneca PLC
LSE:AZN
130.6
9%
14.5
US
Merck & Co Inc
NYSE:MRK
8.3
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.2
2%
3.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DK
ALK-Abello A/S
CSE:ALK B
Average EV/EBIT: 1 700.2
34.6
24%
1.4
US
Eli Lilly and Co
NYSE:LLY
37.9
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.1
13%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
14.5
14%
1
CH
Roche Holding AG
SIX:ROG
11
6%
1.8
CH
Novartis AG
SIX:NOVN
13.2
10%
1.3
UK
AstraZeneca PLC
LSE:AZN
196.9
21%
9.4
US
Merck & Co Inc
NYSE:MRK
10.1
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.1
10%
1